Kolon TissueGene

코오롱티슈진 · 950160

Health Care Pharmaceuticals · KOSDAQ

Large-cap

Market cap US$6.6B (₩9.2T)

Overview

Kolon TissueGene is a biotech company focused on developing cell and gene therapy treatments, primarily targeting joint diseases such as osteoarthritis.

Its products are aimed at patients and are administered through medical professionals in clinical or hospital settings. The company is listed on KOSDAQ, South Korea's technology and small-cap stock exchange, and operates as a clinical-stage biopharmaceutical business.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$2.6K

▼ −2.5% YoY

Operating profit · FY2025

−US$11.4K

Loss narrowed

Net income · FY2025

−US$98.1K

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$2.1K(₩2.8M)	US$2.7K(₩3.7M)	US$2.6K(₩3.6M)
Operating profit	−US$11.4K(−₩15.7M)	−US$11.7K(−₩16.1M)	−US$11.4K(−₩15.7M)
Net income	−US$9.6K(−₩13.2M)	−US$18K(−₩24.8M)	−US$98.1K(−₩135.4M)

Revenue

FY2023US$2.1K
FY2024US$2.7K
FY2025US$2.6K

Operating profit

FY2023−US$11.4K
FY2024−US$11.7K
FY2025−US$11.4K

Net income

FY2023−US$9.6K
FY2024−US$18K
FY2025−US$98.1K

Key ratios (FY2025)

ROE

-303.2%

Debt/Eq

561.6%

Op. margin

-432.7%

Net margin

-3733.3%

Rev. YoY

▼ −2.5%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?